FD&C Act § 801
Section 801 authorizes FDA to refuse admission of articles offered for import when the statutory appearance standard is met. Import Alerts help FDA identify products and firms that may be subject to DWPE.
FDA Import Alerts →Identify the correct Import Alert and removal criteria, document root-cause corrections, organize supporting evidence, prepare the removal request, and respond to FDA follow-up using the guidance that applies to your specific case.
FDA uses Import Alerts to communicate that certain products, firms, shippers, countries/areas, or other identified categories appear to violate FDA requirements and may be subject to Detention Without Physical Examination. The specific alert controls the scope, charge, list structure, evidence for individual-entry release, and removal pathway.
Removal is not simply a request to delete a company name from a database. FDA expects evidence that addresses the condition that created the appearance of violation and gives the agency confidence that future entries will comply. The evidence can differ substantially between contamination, labeling, registration/listing, inspection refusal, CGMP, unapproved product, FSVP, pesticide, device, drug, cosmetic, or other Import Alert issues.
FDA's current general removal guidance says it considers the totality of the evidence and gives “5 clean shipments” as one example of possible evidence. Some specific Import Alerts expressly require or recommend a minimum number of compliant commercial entries; others emphasize inspections, audits, registration/listing corrections, testing, or other evidence.
The precise evidence comes from the specific Import Alert Guidance section and the underlying violation. These are the common evidence categories FDA identifies in its general removal guidance.
Explain how the violation occurred and identify the underlying process, supplier, facility, quality-system, registration, labeling, or other cause.
Document what was fixed and what controls were implemented to prevent recurrence.
Provide objective support that the corrective/preventive measures are working.
Organize the evidence against the current Guidance section and submit it to the FDA contact identified for that alert.
Import Alert removal depends on the specific alert, the listed violation, and the evidence needed to overcome the appearance of violation.
The strategy starts with the specific Import Alert—not a generic petition template.
Confirm the active alert, Red/Yellow/Green List status, product/facility identity, cited charge, entry history, and current Guidance section.
Identify root cause, required corrections, preventive controls, testing/audit/inspection needs, and the objective evidence FDA expects.
Organize the narrative and supporting records so the submission directly addresses the alert-specific removal or exemption criteria.
Submit to the FDA contact identified for the alert and support responses to follow-up questions or additional evidence requests until FDA makes its determination.
Import Alerts are agency guidance used to implement risk-based detention decisions under FDA's import authority. The exact alert Guidance section is central to both entry release and removal strategy.
Section 801 authorizes FDA to refuse admission of articles offered for import when the statutory appearance standard is met. Import Alerts help FDA identify products and firms that may be subject to DWPE.
FDA Import Alerts →FDA's Regulatory Procedures Manual describes procedures associated with Detention Without Physical Examination, including addition, maintenance, and removal considerations.
FDA DWPE / Laboratory Resources →FDA's removal page tells firms to tailor the evidence to the alert, product, problem, and requested list action. Examples include investigation, corrective actions, preventive measures, clean entries, audits, and other objective evidence.
FDA Removal From DWPE →The engagement is customized to the alert, product category, violation, available evidence, and corrective-action history.
Confirm the correct alert number, list status, firm/product scope, charge, Guidance section, and FDA contact path.
Review the underlying compliance problem, prior entries, notices, inspections, testing, warning letters, or other relevant history.
Structure corrective and preventive actions around the actual condition that gave rise to the appearance of violation.
Identify the clean-entry, laboratory, audit, inspection, production, registration/listing, label, or other evidence relevant to the specific alert.
Prepare an indexed request that explains the corrections and connects each supporting record to the alert's removal guidance.
When shipments continue while DWPE is active, review the alert Guidance section for evidence that may overcome the appearance of violation for an individual entry.
Support responses to questions or additional-evidence requests from DIO or the responsible FDA program office within the engagement scope.
Help the business maintain the corrective controls and regulatory processes that supported the removal request.
A single entry can sometimes overcome the appearance of violation while the firm/product remains subject to DWPE. That is different from removal from the Import Alert.
| Individual Entry Release | Import Alert / DWPE Removal | |
|---|---|---|
| Goal | Demonstrate that one detained shipment does not have the violation identified by the Import Alert. | Demonstrate that the underlying condition has been resolved so FDA can consider removing DWPE or granting the applicable exemption/list status. |
| Evidence | Follow the specific alert's Guidance section for evidence applicable to the detained entry. | Broader corrective/preventive evidence, plus alert-specific objective evidence demonstrating future compliance. |
| Effect | May result in release of that individual shipment. | If FDA grants the request, changes the firm's/product's DWPE status under the relevant alert. |
| Does One Release Remove the Alert? | No. | Removal requires a separate FDA determination based on the removal evidence. |
FDA's Import Alert FAQ specifically distinguishes securing release of an individual DWPE shipment from requesting removal from an Import Alert.
Five clean commercial entries are important in many cases, but FDA's current guidance does not make them a universal requirement for every alert.
| Generic Approach | PreferredAlert-Specific Approach | |
|---|---|---|
| Starting Point | Assumes five clean shipments are always the removal rule. | Starts with the current Guidance section of the actual Import Alert. |
| Corrective Actions | May submit clean entries without fully explaining the root cause or preventive controls. | Documents investigation, root cause, corrective actions, preventive measures, and verification. |
| Objective Evidence | Relies on one evidence type. | Uses the evidence the alert calls for: clean shipments, lab reports, audits, inspections, registrations/listings, records, or other proof as applicable. |
| FDA Standard | One-size-fits-all. | FDA states it considers the totality of evidence and that the evidence can differ by alert, product, problem, and requested list action. |
Important: some active Import Alerts expressly require or recommend five or another number of compliant commercial entries. The correct rule is the current Guidance section for the alert involved.
A Warning Letter and an Import Alert can be related, but resolving one does not automatically resolve the other.
| Import Alert Removal | Warning Letter Response | |
|---|---|---|
| Primary Issue | DWPE status under a specific Import Alert. | Specific violations identified in the Warning Letter. |
| How to Respond | Follow the current Import Alert Guidance section and FDA removal instructions. | Follow the instructions and response deadline stated in the actual Warning Letter; many FDA letters request a response within 15 working days. |
| Evidence | Evidence sufficient to address the appearance of violation and support removal/exemption from DWPE. | Corrective actions and supporting documentation addressing each cited violation. |
| Does Resolving One Automatically Close the Other? | No. | No. |
When a case includes both actions, the evidence should be consistent, but each FDA action should be handled through its own stated procedure.
The terminology matters because Red, Yellow, and Green Lists and individual-entry evidence have different meanings.
FDA guidance identifying products, firms, countries/areas, or other categories that appear to violate FDA requirements and may be subject to specified import action.
Detention Without Physical Examination — FDA can detain a product subject to an Import Alert without first physically examining that particular shipment.
Firms/products/countries that have met the criteria for DWPE under an alert that uses a Red List.
FDA describes Yellow List entities as subject to intensified surveillance; FDA's current Import Alerts page states items appearing on a Yellow List are subject to DWPE under that alert.
Firms/products/countries that have met the criteria for exemption from DWPE under an alert that uses a Green List.
The Section 801 import standard allowing FDA to refuse admission when an imported article appears to violate applicable FDA law.
The section of FDA's Regulatory Procedures Manual addressing Detention Without Physical Examination and related Import Alert procedures.
The section of an individual Import Alert describing how DWPE applies, possible evidence for entry release, removal instructions, and contact information.
A non-violative commercial shipment released by FDA that may serve as evidence in removal cases when the specific alert or FDA guidance calls for such evidence.
Action taken to correct the condition that caused or contributed to the violation.
A control implemented to reduce the likelihood that the same problem will recur in future production or shipments.
For a detained entry, the importer of record may request FDA authorization on Form FDA 766 to relabel or recondition the product in an attempt to bring the individual shipment into compliance.
FDA evaluates whether the evidence demonstrates that the underlying condition has been addressed. Weak evidence or the wrong removal theory can slow that review.
The request is built from a generic template instead of the current Guidance section of the actual Import Alert.
Clean entries can be important evidence, but they do not replace investigation, corrective action, or other alert-specific proof.
The submission describes a correction but does not explain why the violation occurred or how recurrence is prevented.
New procedures are described but the evidence does not show that they were implemented and are functioning.
FDA states that evidence shipments should reflect normal commercial shipping patterns over a reasonable period rather than being artificially structured only for the petition.
Reports are missing product identity, sampling context, methodology, supporting records, or other information needed to evaluate the results.
Evidence that supports release of one shipment is submitted as though that individual release automatically removes the DWPE listing.
The submission is not actively managed when FDA asks questions or requests additional documentation, leaving the removal review unresolved.
These services directly support import-entry readiness, detention response, corrective compliance, and preventing repeat import problems.
Monitor available FDA entry status, document requests, Notices of FDA Action, and ongoing import compliance issues.
Review detained or refused entries and organize the appropriate documentation, corrective action, or next-step strategy.
For covered imported foods, build and maintain the Foreign Supplier Verification Program required of the FDA-defined FSVP importer.
Prepare and file Prior Notice for covered imported food shipments within the applicable regulatory timing requirements.
Correct food-label, ingredient, allergen, Nutrition Facts, and claim issues that can contribute to import problems.
Food Facility Registration, U.S. Agent, FSVP, Prior Notice, labeling, FCE/SID, HACCP, and related import support.
Direct answers about DWPE, Red/Yellow/Green Lists, clean shipments, removal evidence, individual-entry release, laboratory testing, reconditioning, Warning Letters, and FDA follow-up.
An FDA Import Alert is agency guidance used to notify FDA staff, the import community, and the public about products, firms, countries/areas, or other categories that appear to violate FDA requirements and may be subject to specified import action, including Detention Without Physical Examination.
DWPE means Detention Without Physical Examination. When a product is subject to DWPE under an Import Alert, FDA can detain the shipment based on the alert without first physically examining that particular shipment.
A product subject to DWPE can be detained and may be refused unless the importer overcomes the appearance of the violation. FDA's Guidance section for the specific Import Alert explains the evidence that may be appropriate for release of an individual entry.
FDA maintains a public Import Alert search database that can be searched by keywords, firm name, product, country/area, alert number, and other information. FDA states that the database is updated in real time.
FDA defines the Red List as firms, products, and/or countries that have met the criteria for DWPE under an Import Alert.
FDA describes Yellow List entities as subject to intensified surveillance; FDA's current Import Alerts page also states that firms/products appearing on a Yellow List are subject to DWPE under that alert.
FDA defines the Green List as firms, products, and/or countries that have met the criteria for exemption from DWPE under an Import Alert.
Start with the Guidance section of the specific Import Alert. FDA's general removal guidance says the petition should be tailored to the alert, product, problem, and requested removal action and may include investigation findings, corrective actions, preventive measures, and objective evidence supporting future compliance.
No. FDA's general removal page lists '5 clean shipments' as an example of evidence and states that it considers the totality of evidence. Some specific Import Alerts expressly require or recommend a minimum of five or another number of compliant commercial entries. The current Guidance section of the specific Import Alert controls the strategy.
FDA's Import Alert FAQ says there is no exact universal quantity or timeframe for what counts as a routine commercial entry, but the entries should occur over a reasonable time and reflect normal shipping patterns.
Usually not by itself. Release of an individual entry and removal from DWPE are separate issues. The removal request must satisfy the evidence expectations of the specific Import Alert and demonstrate that the condition giving rise to the appearance of violation has been addressed.
Yes, depending on the alert and violation. FDA states that when a shipment is subject to DWPE, the importer or consignee has the right to provide testimony or evidence to demonstrate that the product does not have the violation listed in the Import Alert. The Guidance section explains what may be needed.
Common evidence can include the firm's investigation, root-cause findings, corrective actions, preventive measures, production or quality records, clean commercial entries, third-party laboratory reports, audits, inspection evidence, registrations/listings, labels, or other information relevant to the violation and specific alert.
FDA's current Import Alert pages commonly state that a firm and/or a representative of the firm may petition for removal from DWPE. The appropriate representative and submission path should be confirmed from the specific alert.
FDA's general removal page currently directs most petitions to ImportAlerts2@fda.hhs.gov, but it also states that certain alerts require petitions to go directly to the Compliance Officer or another contact identified in that Import Alert's Guidance section.
FDA's current Import Alert removal instructions do not list a petition filing fee. Professional consulting, laboratory testing, audits, reconditioning, storage, demurrage, customs, or other case costs are separate and can vary.
FDA does not publish a guaranteed universal decision time for all Import Alert removal requests. Timing depends on the alert, program office, complexity, completeness of corrective evidence, whether FDA requests more information, and whether inspection or additional verification is necessary.
No. FDA determines whether the evidence is sufficient to change the DWPE status. A consultant can improve organization, identify missing evidence, prepare the submission, and support follow-up, but cannot guarantee the agency's decision or timing.
Individual-entry release focuses on demonstrating that one shipment does not have the violation identified in the alert. Import Alert removal focuses on demonstrating that the underlying condition has been resolved so FDA can consider changing the firm's or product's ongoing DWPE status.
An Import Alert is an import-enforcement tool associated with DWPE. A Warning Letter communicates FDA's position about significant violations and requests corrective action. A company can be dealing with both at the same time, and resolving one does not automatically resolve the other.
No response deadline should be assumed without reading the actual letter. Many FDA Warning Letters request a response within 15 working days, but the firm should follow the deadline and instructions stated in the specific letter.
Yes. FDA maintains Import Alerts across multiple regulated product categories. The legal charge, evidence, responsible FDA program office, testing, registration/listing issues, and removal criteria can differ substantially by product category and specific alert.
No. RPM Chapter 9-8 provides the overall DWPE framework, but each Import Alert can have its own Guidance section, evidence expectations, responsible FDA center/program office, and list-removal or exemption criteria.
Yes. A firm or product can potentially be affected by multiple Import Alerts. Each alert and underlying violation should be reviewed separately, although FDA may sometimes allow related evidence to support more than one alert when the specific Guidance permits it.
A name change should not be treated as a removal strategy. FDA's public alert listing and underlying compliance information need to be corrected through appropriate regulatory channels, and the condition giving rise to DWPE still has to be addressed.
A representative may be able to submit a request, but the precise role of a U.S. Agent differs by FDA program. A food-facility U.S. Agent, drug U.S. Agent, device U.S. Agent, importer, attorney, or other representative should not be assumed to have identical authority in every case. The specific Import Alert and engagement should be reviewed.
Not as a universal Import Alert rule. Separate FDA programs can require a U.S. Agent for certain foreign registered facilities, but the requirement comes from the applicable registration program—not simply from filing a DWPE removal request.
Yes, when analytical evidence is relevant to the violation and the specific Import Alert. FDA's private laboratory guidance notes that lab reports can be useful for overcoming the appearance of a violation in appropriate DWPE cases. Some alerts have specific analytical or laboratory expectations.
Yes, in some cases. FDA's general removal guidance identifies third-party audits as an example of possible evidence, and some specific alerts expressly discuss inspection or audit information. Whether an audit is useful depends on the violation and alert.
Yes, for some alerts and violations FDA may determine that an inspection or other verification is necessary before considering the appearance of violation resolved. The specific Import Alert Guidance and responsible program office should be reviewed.
When an imported product is detained because it appears to violate FDA requirements, the importer of record may submit Form FDA 766 requesting permission to relabel or recondition the product in an attempt to bring that individual shipment into compliance. FDA can grant or deny the proposal.
No. Reconditioning concerns the admissibility of the individual detained shipment. It does not by itself remove a firm or product from DWPE under an Import Alert.
A business can offer shipments for import while DWPE remains in effect, but the entries remain subject to the applicable Import Alert. The importer should understand the Guidance section, evidence expectations, costs, and risks before continuing shipments.
FDA's Import Alert FAQ states that in most cases, publication of a firm/product on the Import Alert serves as notification to the firm.
Send the Import Alert number or link if known, firm and product name, country, FDA entry numbers, Notices of FDA Action, laboratory results, warning letters or inspection records, prior correspondence, corrective actions already taken, and any registration/listing or product documentation relevant to the cited issue.
Pricing is custom. Scope depends on the Import Alert, product category, number of affected products/facilities, violation complexity, root-cause work, testing/audit/inspection evidence, clean-entry strategy, and level of FDA correspondence support required.
Yes. When useful, Import Alert removal work can be scoped together with FDA shipment monitoring, individual-entry detention/refusal assistance, laboratory or sampling coordination, FSVP, label correction, or other directly related compliance work. Any bundled pricing should be stated in the written quote rather than assumed.
The business should continue the corrective and preventive controls that supported the removal and verify its current status in the Import Alert database before future shipments. Removal from one Import Alert does not waive other FDA requirements or prevent future enforcement if new violations occur.
Send us the Import Alert number, firm/product information, entry history, Notices of FDA Action, testing or inspection records, and corrective actions already taken. We will review the likely removal pathway and scope.